Headed up by a mature team of serial entrepreneurs and managers from MIT, Harvard and Childrens Hospital Boston, EntraTympanic is an early-stage medical device firm developing a new device and in-office procedure for the treatment of middle ear infections: both pediatric and adult. In 2013, in a widely published ddecision, the American Academy of Pediatrics recommended new guidelines focused on better diagnosis of ear infections: watchful waiting and decreased use of systemic antibiotics. Though well intentioned, the now current practice of a 2-3 day watchful waiting period which leaves the child in severe pain, as well as the escalating drug resistance of bacterial otopathogens resulting from the past and continuing over use of systemic antibiotics. The device under development by EntraTympanic is designed to provide instant pain relief and eliminates the use of systemic antibiotics by draining the fluid from, and delivering medication to the middle ear. With 25M annual US episodes of this complaint, this approach could represents a multi-billion dollar US market opportunity to create a new standard of care. The firm's proprietary EToscope is a Class II device and qualifies for US FDA 510(k) approval.
